Leading through
expertise

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 40 years of successful biopharmaceutical experience managing clinical development and commercial operations. Prior to Nektar Therapeutics, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington’s disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion.

Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as Corporate Vice President and General Manager of their U.S. Therapeutics division and was responsible for the development of drugs including Betaseron^® (Interferon beta-1b) for multiple sclerosis and Fludara^® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was Vice President of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a Senior Associate with Arthur Andersen and Co.

Mr. Robin serves as a director of the Biotechnology Industry Organization, the world’s largest biotechnology industry trade organization. He holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey.

Robert Bacci joined Nektar in 2001 and was appointed Nektar’s Chief People Officer and Head of Quality & Facilities in 2024. In his role, Mr. Bacci oversees multiple facets of operations, including human resources, quality assurance, facilities management, and environmental strategy. Before he was appointed Chief People Officer, Mr. Bacci served as Senior Vice President of Human Resources and Facilities Operations, overseeing site operations in Huntsville, Alabama.

Prior to joining Nektar, Mr. Bacci served as an industrial hygienist at multiple firms where he led complex environmental investigations and risk assessments. He has previously served as an affiliate faculty member in the M.S. Program in Organizational Leadership at the Union University and Institute in Cincinnati, Ohio. He also holds professional certifications, including Certified Safety Professional (CSP) from the Board of Certified Safety Professionals and as a Certified Industrial Hygienist (CIH) from the American Board of Industrial Hygiene.

Mr. Bacci received his M.B.A. from John F. Kennedy University and his B.S. in Industrial Hygiene from California State University at Fresno.

Jason Barnard was appointed Chief Accounting Officer in January 2025. In this role, he leads the company’s accounting organization and is responsible for the company’s SEC reporting and maintaining its internal control environment. Mr. Barnard has over 18 years of professional experience and has held positions of increasing responsibility at Nektar since joining in 2016, including serving as the company’s Corporate Controller since 2020.

Prior to joining Nektar, Mr. Barnard worked at Blackhawk Network where he established the SEC reporting and technical accounting function, from Blackhawk’s IPO through its first SEC filings and multiple business acquisitions.

Mr. Barnard is a Certified Public Accountant (Inactive). He received his M.S. in Accountancy from Golden Gate University, and his B.A. in Linguistics and Classical Languages from UC Berkeley.

Ken Franke joined Nektar in 2019 and currently serves as Senior Vice President, Biologics Process Development and Manufacturing, where he leads technical teams responsible for supporting Nektar’s biologics products produced at contract manufacturing sites globally. In this role, Dr. Franke oversees analytical development, early- and late-stage process development, process characterization and clinical supply chain management.

Dr. Franke brings over 25 years of experience in biotechnology development and manufacturing. Prior to joining Nektar, he held technical leadership positions at Lonza Hayward, where he led teams supporting clinical bulk drug substance manufacturing, tech transfer and pilot scale operations, and previously held global leadership roles at Shire Pharmaceuticals supporting external drug substance and drug product manufacturing for the Shire commercial biologics and plasma derived product portfolio.

Dr. Franke received his Ph.D. in Plant Biology from the University of California, Davis, and his B.S. in Botany from UC Davis. He completed postdoctoral research at the Plant Gene Expression Center at UC Berkeley.

Sandra Gardiner was appointed acting Chief Financial Officer of Nektar Therapeutics in April 2023. Sandra is a partner at FLG Partners, a leading CFO services firm in the Silicon Valley and a skilled business and finance executive with over 30 years of experience as an EVP and CFO at private and public companies in the Life Sciences sector. She served as the Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer of Pulse Biosciences, Inc., a bioelectric medicine company, since November 2019 until she joined FLG Partners. Prior to joining Pulse Biosciences, she’s held CFO roles in both domestic and global companies, operating as a director to international subsidiaries throughout Europe, Asia Pacific and Latin America. Her tenure includes leadership positions at development-stage, pre-commercial to enterprise, commercial $350M+ biotech and medtech companies. She’s been involved in executing numerous financial transactions, including IPOs, secondary offerings, private placements, reverse mergers, rights offerings, ATMs and debt facilities raising over $1Bn in capital and completed two M&A transactions.

Charleen Jue joined Nektar in 2010 and currently serves as Senior Vice President, Clinical Development Operations, where she leads an integrated global development operations function accountable for the strategy, execution and compliance of clinical trials while overseeing Nektar’s clinical trial portfolio.

Ms. Jue brings over 25 years of experience in clinical development operations. Prior to rejoining Nektar, she served as Vice President of Clinical Operations at Genfit Corp, where she led global NASH and PBC programs. Previously, she held leadership roles at Cubist Pharmaceuticals (a Merck subsidiary), University of Minnesota Cancer Center, MGI Pharma, TransOral Pharmaceuticals, OSI Pharmaceuticals, Chiron Corporation, Cerus Corporation and Genentech.

Ms. Jue has extensive experience with CRO partnerships, regulatory compliance and successful drug approvals, having contributed to multiple marketed products including Dacogen^®, Tarceva^®, Nutropin^® and Pulmozyme^®.

Ms. Jue holds an RN License and received her B.S. in Biology from New Mexico State University.

Brian Kotzin, MD, who was serving as the Company’s strategic advisor to the rezpegaldesleukin program since April 2023, has assumed the responsibilities of interim Chief Medical Officer. From 2017 to 2023, Dr. Kotzin supported the clinical development of rezpegaldesleukin in several different capacities at the Company, including as Chief Medical Officer and Head of Clinical Development. Dr. Kotzin has over 40 years of expertise in immunology and has extensive development and management experience. From 2004 to 2015, Dr. Kotzin was at Amgen, where he served as Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area, directing the global development efforts for Amgen product candidates in the inflammation area. During his time at Amgen, he also served as Vice President of Medical Sciences, which encompassed early development, biomarker development, and clinical immunology. Prior to entering the life sciences industry, Dr. Kotzin held several positions in academia, including a professor at the University of Colorado Health Sciences Center, where his research focused on the immunopathogenesis of autoimmune disease. He has also held leadership roles at several national organizations, including as a member of the American College of Rheumatology (ACR) Board of Directors and is currently an elected Master of the ACR, Member and Chairperson of the NIH Immunological Sciences Study Section, Chairperson of the NIH Autoimmunity Centers of Excellence, and Member of the Board of Directors for the Federation of Clinical Immunology Societies. He has previously served on the Board of Directors of Rigel Pharmaceuticals, Inc., Vera Therapeutics, Inc., Biora Therapeutics, Inc., and Kyverna Therapeutics, Inc. He currently serves on the Board of Directors of Argenx SE and Genascence Corporation.

Dr. Kotzin received an M.D. from Stanford University and a bachelor’s degree in mathematics from the University of Southern California. He is board certified in rheumatology and internal medicine.

Takahiro Miyazaki joined Nektar in 2016 and currently serves as Senior Vice President, Head of Research. In this role, Mr. Miyazaki oversees preclinical programs in autoimmune disease indications, supports clinical programs including rezpegaldesleukin and NKTR-255 and provides scientific expertise to business development initiatives.

Mr. Miyazaki brings over 23 years of experience in biopharmaceutical research for target discovery and drug development of both small and large molecules in immune-mediated diseases. Prior to joining Nektar, he spent a decade at Takeda Pharmaceutical Company, advancing from Assistant Research Head, Pharmacology Research Laboratories to Head of Biology & Pharmacology in the Inflammation Drug Discovery Unit. Earlier in his career, he held research positions at Astellas Pharma.

Mr. Miyazaki received his M.S. and B.A. degrees in Bioscience from Tokyo Institute of Technology, with a focus on molecular and cellular biology and immunology.

Jennifer Ruddock currently serves as Chief Business Officer, leading corporate and business development and corporate strategy for Nektar. She also oversees and leads investor relations, corporate communications, and public and government affairs functions. Ms. Ruddock’s professional experience spans over 25 years in biotechnology, technology and finance. Prior to joining Nektar, Ms. Ruddock held leadership roles at multiple public companies, including Catellus Development Corporation (acquired by ProLogis) and Tumbleweed Communications (acquired by Axway). Prior to that, she was at Montgomery Securities (acquired by Bank of America), a San Francisco-based investment bank which specialized in technology and healthcare sectors.

Ms. Ruddock serves on the Board of Directors of Gannet BioChem, a leading specialty chemical CDMO, the California Life Sciences Association (CLSA), and is a member of the Public Policy Committee of the San Francisco Chamber of Commerce. She is also a board member of the San Francisco Foster Youth Fund, a non-profit providing educational grants to at-risk youth in San Francisco foster care.

Ms. Ruddock received her B.A. degree in neuroscience from Colgate University in 1991.

Mark A. Wilson was appointed Chief Legal Officer in July 2022. In this role, Mr. Wilson oversees all legal matters pertaining to the company, including contracts, corporate governance, securities law, SEC reporting, litigation, and all intellectual property matters including patent, copyright, and trademark matters. Mr. Wilson has over 20 years in the legal field, with a particular emphasis on intellectual property. Prior to his appointment as Nektar’s General Counsel in July 2016, Mr. Wilson led Nektar’s intellectual property department with oversight for the company’s extensive patent portfolio, including the preparation and prosecution of patent applications.

Prior to joining Nektar in 2002, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he successfully represented both early-stage and Fortune 500 companies.

Mr. Wilson received his J.D. from Seton Hall University, School of Law, and his B.S. in pharmacy from Rutgers University, College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the California Bar.

Jonathan Zalevsky was appointed Nektar’s Chief Research & Development Officer in October 2019 to lead all aspects of the R&D organization, including research, clinical development, regulatory affairs, and biologics process development. Dr. Zalevsky joined the Company in 2015 and has served as our Chief Scientific Officer since 2017. During his tenure at Nektar, Dr. Zalevsky’s expertise in immunology, and across biological modalities and therapeutic areas, has helped fuel the growth of the company’s immuno-oncology and immunology pipeline. Dr. Zalevsky led the early development for rezpegaldesleukin and NKTR-0165.

Prior to joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development and marketed products. Prior to his work at Takeda, Dr. Zalevsky worked in research and development at Xencor, where he oversaw the discovery and development of Xencor’s first four clinical-stage assets.

Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual B.S. degrees in Biochemistry and Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder.